This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study
by Zacks Equity Research
Lilly (LLY) is conducting five studies on Olumiant (baricitinib) under the atopic dermatitis (AD) program and BREEZE-AD7 is the third study to be completed this year.
Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer
by Zacks Equity Research
Celgene's (CELG) oncology portfolio gets a boost with the FDA approval of Inrebic for rare bone marrow cancer.
Incyte (INCY) Q2 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Incyte (INCY) reports better-than-expected results for the second quarter of 2019, owing to strong Jakafi sales.
Incyte (INCY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Incyte (INCY) delivered earnings and revenue surprises of 53.06% and 5.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on top- and bottom-line numbers along with other pipeline updates, when Zoetis reports Q2 results.
Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Exelixis' (EXEL) second-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.
Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings?
by Zacks Equity Research
Investors are expected to focus on the HIV franchise's performance and other pipeline updates, when Gilead (GILD) reports second-quarter 2019 results.
Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings?
by Zacks Equity Research
Investors will primarily focus on Jakafi sales and pipeline updates, when Incyte (INCY) reports second-quarter 2019 results.
5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2
by Zacks Equity Research
We take a look at the overall drug/biotech sector's performance and five stocks that are poised to beat on earnings in the second quarter of 2019.
Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Merck's Keytruda sBLAs for 6-Week Dosing to be Reviewed by FDA
by Zacks Equity Research
FDA accepts Merck's (MRK) sBLAs for a six-week dosing schedule of Keytruda for melanoma and multiple other indications
Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab
by Zacks Equity Research
Incyte (INCY) inks a licensing deal with Zai Lab to develop and commercialize INCMGA0012 for hematology and oncology indications in Greater China.
The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal
by Zacks Equity Research
A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.
Merck's Keytruda Gets 2nd Label Expansion Approval in June
by Zacks Equity Research
Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.
Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
by Zacks Equity Research
Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.
Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock
by Zacks Equity Research
Here are five reasons why investors may consider betting on Merck (MRK) stock
Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study
by Zacks Equity Research
Pfizer's (PFE) study on JAK inhibitor Xeljanz XR demonstrates the efficacy of the medicine when used as a monotherapy without methotrexate.
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Incyte Begins Phase III Study for Treatment of Duct Cancer
by Zacks Equity Research
Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.
Celgene (CELG) Presents Data on Pipeline Candidates at ASCO
by Zacks Equity Research
Celgene (CELG) presents data on myelofibrosis candidate from a phase II study and an oncology candidate at ASCO.
Novartis (NVS) Announces Various Data Presentations at ASCO
by Zacks Equity Research
Novartis (NVS) announces a number of data presentations at the ASCO 2019 annual meeting.
Mesoblast Starts Rolling BLA Submission for Remestemcel-L
by Zacks Equity Research
Mesoblast (MESO) begins the rolling submission of a BLA for its lead product, candidate remestemcel-L, to the FDA for treating children with steroid-refractory acute graft versus host disease.